Literature DB >> 31793986

Clinicopathologic Features of Diencephalic Neuronal and Glioneuronal Tumors.

Cheng-Ying Ho1, Miriam Bornhorst2, M Isabel Almira-Suarez3, Kliment Donev4, Marjorie Grafe5, Heather Gordish-Dressman6, Fausto J Rodriguez1.   

Abstract

Neuronal/mixed glioneuronal tumors are central nervous system neoplasms composed of neoplastic neuronal cell components or a mixture of glial and neuronal elements. They occur in cerebral hemispheres, posterior fossa, and spinal cord. Compared with other tumors at these locations, diencephalic neuronal/glioneuronal tumors are very rare and therefore not well characterized. We hereby performed clinicopathologic evaluation on 10 neuronal/glioneuronal tumors arising from the diencephalic region. Morphologically, these tumors resemble their histologic counterparts in other locations, except that lymphocytic infiltrates and microcalcifications are more common than Rosenthal fibers or eosinophilic granular bodies. The BRAFV600 mutation rate is 75%. Given the high percentage of samples being small biopsy specimens, the subtle histologic features and molecular findings greatly aided in establishing the pathologic diagnosis in several cases. At a median follow-up of 42 months, 71% of the tumors demonstrated radiological recurrence or progression, with median progression-free survival of 18 months. Recurrence/progression is observed in tumors across different histologic subtypes, necessitating additional therapies in 56% of the cases. Despite their bland histology, diencephalic neuronal/glioneuronal tumors are not clinically indolent. Their frequent recurrences warrant a close follow-up, and the prevalent BRAF mutation makes MAPK pathway inhibition a plausible treatment option when conventional therapies fail.
© 2019 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  BRAF V600E; Diencephalic; Gangliocytoma; Ganglioglioma; Ganglion cell tumor; Glioneuronal tumor; Rosette-forming glioneuronal tumor

Mesh:

Substances:

Year:  2020        PMID: 31793986      PMCID: PMC7850088          DOI: 10.1093/jnen/nlz115

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  30 in total

1.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.

Authors:  Genevieve Schindler; David Capper; Jochen Meyer; Wibke Janzarik; Heymut Omran; Christel Herold-Mende; Kirsten Schmieder; Pieter Wesseling; Christian Mawrin; Martin Hasselblatt; David N Louis; Andrey Korshunov; Stefan Pfister; Christian Hartmann; Werner Paulus; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2011-01-29       Impact factor: 17.088

2.  Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.

Authors:  Libero Santarpia; Steven I Sherman; Anna Marabotti; Gary L Clayman; Adel K El-Naggar
Journal:  Hum Pathol       Date:  2009-02-05       Impact factor: 3.466

3.  Ganglioglioma in children and young adults: single institution experience and review of the literature.

Authors:  Wafik Zaky; Shekhar S Patil; Minjeong Park; Diane Liu; Wei-Lien Wang; Khalida M Wani; Susana Calle; Leena Ketonen; Soumen Khatua
Journal:  J Neurooncol       Date:  2018-06-07       Impact factor: 4.130

4.  Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases.

Authors:  Andrew M Donson; Bette K Kleinschmidt-DeMasters; Dara L Aisner; Lynne T Bemis; Diane K Birks; Jean M Mulcahy Levy; Amy A Smith; Michael H Handler; Nicholas K Foreman; Sarah Z Rush
Journal:  Brain Pathol       Date:  2013-12-23       Impact factor: 6.508

5.  Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.

Authors:  Cordelia Luyken; Ingmar Blümcke; Rolf Fimmers; Horst Urbach; Otmar D Wiestler; Johannes Schramm
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

6.  Central nervous system gangliogliomas. Part 2: Clinical outcome.

Authors:  F F Lang; F J Epstein; J Ransohoff; J C Allen; J Wisoff; I R Abbott; D C Miller
Journal:  J Neurosurg       Date:  1993-12       Impact factor: 5.115

7.  Integrative genomics viewer.

Authors:  James T Robinson; Helga Thorvaldsdóttir; Wendy Winckler; Mitchell Guttman; Eric S Lander; Gad Getz; Jill P Mesirov
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908

Review 8.  Cerebellar ganglioglioma.

Authors:  Badr Fedoul; Zouhayr Souirti
Journal:  Pan Afr Med J       Date:  2012-05-22

9.  Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.

Authors:  Parvez M Lokhandwala; Li-Hui Tseng; Erika Rodriguez; Gang Zheng; Aparna Pallavajjalla; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  BMC Cancer       Date:  2019-07-05       Impact factor: 4.430

10.  Posterior fossa and spinal gangliogliomas form two distinct clinicopathologic and molecular subgroups.

Authors:  Kirti Gupta; Wilda Orisme; Julie H Harreld; Ibrahim Qaddoumi; James D Dalton; Chandanamali Punchihewa; Racquel Collins-Underwood; Thomas Robertson; Ruth G Tatevossian; David W Ellison
Journal:  Acta Neuropathol Commun       Date:  2014-02-14       Impact factor: 7.801

View more
  2 in total

1.  Pineal region ganglioglioma: A neoplasm with a bimodal age distribution.

Authors:  Osama A Al-Dalahmah; Linda Wang; Susan J Hsiao; Chun-Chieh Lin; Mahesh M Mansukhani; Peter Canoll; Jeffrey N Bruce; George Zanazzi
Journal:  Surg Neurol Int       Date:  2022-06-10

2.  Anaplastic ganglioglioma originating from the medulla oblongata: case report.

Authors:  Wei Han; Wei Guan; Jia Shi
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.